(Q42991917)

12 November 2017

title

Should patients with early loss of serum HCV-RNA during alpha interferon therapy for chronic hepatitis C be treated for 6 or 12 months? (English)

1 reference

12 November 2017

1 reference

Bellobuono A

1

1 reference

12 November 2017

Mondazzi L

2

1 reference

12 November 2017

Tempini S

3

1 reference

12 November 2017

Chiodo F

4

1 reference

12 November 2017

Magliano E

5

1 reference

12 November 2017

Mondini C

6

1 reference

12 November 2017

Idéo G

7

1 reference

12 November 2017

language of work or name

1 reference

1 January 1999

1 reference

12 November 2017

published in

Journal of Hepatology

1 reference

12 November 2017

volume

30

1 reference

12 November 2017

issue

1

1 reference

12 November 2017

page(s)

8-13

1 reference

Interferon for non-A, non-B chronic hepatitis

12 November 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2899%2980002-6

7 January 2021

Hepatitis C viraemia rebound after “successful” interferon therapy in patients with chronic non‐A, non‐B hepatitis

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2899%2980002-6

7 January 2021

A survey of adverse events in 11,241 patients with chronic viral hepatitis treated with alfa interferon.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2899%2980002-6

7 January 2021

Predictive factors in the response to interferon therapy in chronic hepatitis C.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2899%2980002-6

7 January 2021

Loss of serum HCV RNA at week 4 of interferon-alpha therapy is associated with more favorable long-term response in patients with chronic hepatitis C.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2899%2980002-6

7 January 2021

Permanent response to alpha-interferon therapy in chronic hepatitis C is preceded by rapid clearance of HCV-RNA from serum.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2899%2980002-6

7 January 2021

Serial assay of hepatitis C virus RNA in serum for predicting response to interferon-alpha therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2899%2980002-6

7 January 2021

Significance of early measurement of serum hepatitis C virus RNA in predicting response to interferon therapy in patients with chronic hepatitis C.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2899%2980002-6

7 January 2021

Meta-analysis of interferon randomized trials in the treatment of viral hepatitis C: effects of dose and duration

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2899%2980002-6

7 January 2021

Histological grading and staging of chronic hepatitis

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2899%2980002-6

7 January 2021

Single-Step Method of RNA Isolation by Acid Guanidinium Thiocyanate–Phenol–Chloroform Extraction

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2899%2980002-6

7 January 2021

Avoiding false positives with PCR

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2899%2980002-6

7 January 2021

Significance of serum hepatitis C virus RNA levels in chronic hepatitis C.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2899%2980002-6

7 January 2021

Typing hepatitis C virus by polymerase chain reaction with type-specific primers: application to clinical surveys and tracing infectious sources

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2899%2980002-6

7 January 2021

Characterization of the genomic sequence of type V (or 3a) hepatitis C virus isolates and PCR primers for specific detection

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2899%2980002-6

7 January 2021

Classification of hepatitis C virus into six major genotypes and a series of subtypes by phylogenetic analysis of the NS-5 region

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2899%2980002-6

7 January 2021

A proposed system for the nomenclature of hepatitis C viral genotypes

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2899%2980002-6

7 January 2021

Long-term efficacy of ribavirin plus interferon alfa in the treatment of chronic hepatitis C.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2899%2980002-6

7 January 2021

Hepatitis C RNA in liver of chronic hepatitis C patients before and after interferon alfa treatment.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2899%2980002-6

7 January 2021

Hepatic hepatitis C virus RNA as a predictor of a long-term response to interferon-alpha therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2899%2980002-6

7 January 2021

Replication of hepatitis C virus: catching it in the act.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2899%2980002-6

7 January 2021

10.1016/S0168-8278(99)80002-6

Identifiers

DOI

1 reference

12 November 2017

1 reference